Radiotherapy after radical prostatectomy in patients with prostate-specific antigen elevation

Frontiers of Radiation Therapy and Oncology

Volumn 36, Issue , 2002, Pages 35-42

  Wiegel, T ^a   Hinkelbein, W ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; ADJUVANT THERAPY; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FOLLOW UP; HUMAN; MALE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PROSTATE TUMOR; PROSTATECTOMY; RADIATION DOSE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0036359257     PISSN: 00719676     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000061327     Document Type: Article

References (33)

1. American Society for Therapeutic Radiology and Oncology Consensus Panel: Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. J Clin 1999;17:1155-1163.
2. Anscher M, Prosnitz LR: Multivariate analysis of factors predicting local relapse after radical prostatectomy-possible indications for postoperative radiotherapy. Int J Radiat Oncol Biol Phys 1991; 21:941-947.
3. Cadeddu JA, Partin AW, De Weese TL, Walsh PC: Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 1998;159:173-178.
4. Catalona WJ, Smith DS: Five-year tumour recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152:1837-1842.
5. Coetzee LJ, Hars V, Paulson DF: Postoperative prostate antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology 1997;47:232-235.
6. Dearnalay DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, Yarnold J, Horwich A: Comparison of radiation side effects of conformal and conventional radiotherapy in prostate cancer: A andomized trial. Lancet 1999;353:267-272.
7. Forman JD, Meetze K, Pontes E, Wood DP, Shamsa F, Rana T, Porter AT: Therapeutic irradiation for patients with an elevated post-prostatectomy prostate-specific antigen level. J Urol 1997;158: 1436-1440.
8. Formenti SC, Lieskovsky G, Simoneau AR, Skinner D, Groshen S, Chen SC, Petrovich Z: Impact of moderate dose of postoperative radiation on urinary continence and potency in patients with prostate cancer treated with nerve-sparing prostatectomy. J Urol 1996;155:616-619.
9. Kaplan ID, Bagshaw MA: Serum prostate-specific antigen after post-prostatectomy radiotherapy. Urology 1992;39:401-406.
10. Keisch ME, Perez CA, Grigsby PW, Bauer WC, Catalona W: Preliminary report on 10 patients treated with radiotherapy after radical prostatectomy for isolated elevation of serum PSA levels. Int J Radiat Oncol Biol Phys 1990;19:1503-1506.
11. Lange PH, Lightner DJ, Medini E, Reddy PK, Vesella RL: The effect of radiation therapy after radical prostatectomy in patients with elevated prostate-specific antigen levels. J Urol 1990;144: 927-932.
12. Lightner DJ, Lange PH, Reddy PK, Moore L: Prostate-specific antigen and local recurrence after radical prostatectomy. J Urol 1990;144:921-926.
13. Link P, Freiha FS, Stamey TA: Adjuvant radiation therapy in patients with detectable prostatespecific antigen following radical prostatectomy. J Urol 1991;145:532-534.
14. Morgan WR, Bergstrahl EJ, Zincke H: Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology 1993;41:116-120.
15. Morris MM, Dallow KC, Zietman AL, Park J, Althausen A, Heney NM, Shipley WU: Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 1997;38:731-736.
16. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT: Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995;154:1818-1824.
17. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC: Serum PSA after anatomic radical prostatectomy: The John Hopkins experience after 10 years. Urol Clin North Am 1993;20:713-725.
18. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, Epstein JI, Walsh PC: Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994;43:649-659.
19. Perez CA, Eisbruch A: Role of postradical prostatectomy irradiation in carcinoma of the prostate. Semin Radiooncol 1993;3:198-209.
20. Pisansky TM, Kozelsky TF, Myers RP, Hillman DW, Blute ML, Buskirk SJ, Cheville JC, Ferrigni RG, Schild SE: Radiotherapy for isolated serum prostate-specific antigen elevation after prostatectomy for prostate cancer. J Urol 2000;163:845-850.
21. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-1597.
22. Schild SE, Wong WW, Grado GL, Buskirk SJ, Robinow JS, Frick LM, Ferrigni RG: Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy. Mayo Clin Proc 1994;69:613-619.
23. Syndikus I, Pickles T, Kostashuk E, Sullivan LD: Postoperative radiotherapy for stage pT3 carcinoma of the prostate: Improved local control. J Urol 1996;155:1983-1986.
24. Van Cangh PJ, Richard F, Lorge F, Castille Y, Moxhon A, Opsomer R, de Visscher L, Wese FX, Scalliet P: Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: Results of a prospective randomized study. J Urol 1998;159:164-166.
25. Van den Ouden D, Bentvelsen FM, Boeve ER, Schröder FH: Positive margins after radical prostatectomy: Correlation with local recurrence and distant progression. Br J Urol 1993;72:489-494.
26. Wiegel T, Bressel M, Arps H, Hübener KH: Radiotherapy of local recurrence following radical prostatectomy. Strahlenther Onkol 1992;168:333-336.
27. Wiegel T, Bressel M: Adjuvant radiotherapy following radical prostatectomy - Results of 56 atients. Eur J Cancer 1995;31A:5-11.
28. Wiegel T, Hinkelbein W, Steiner U, Miller K: Postoperative radiotherapy for stage pT3 carcinoma of the prostate: Improved local control. Letter to the editor. J Urol 1997;159:965-966.
29. Wiegel T, Steiner U, Hinkelbein W: Adjuvante Strahlentherapie nach radikaler Prostatektomie -Indikationen, Ergebnisse, Nebenwirkungen. Strahlenther Onkol 1997;173:309-315.
30. Wiegel T, Hinkelbein W: Lokal fortgeschrittenes Prostatakarzinom (T2b-T4 No) ohne und lokoregionär fortgeschrittenes Prostatakarzinom (Tx N+) mit Lymphknotenmetastasen. Ist eine Strahlentherapie der pelvinen Lymphabflusswege indiziert oder nicht indiziert? Strahlenther Onkol 1998; 174:231-236.
31. Wu JJ, King SC, Montana GS, McKinstry CA, Anscher MS: The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 1995;32:317-323.
32. Zietman AL, Edelstein RA, Coen JJ, Babayan RK, Krane RJ: Radical prostatectomy for adenocarcinoma of the prostate: The influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 1994;43:828-833.
33. Zimmermann FB, Molls M: Three-dimensional treatment planning: Principles and practice. Onkologie 1998;21:474-484.